Connection

William Spencer to Cardiomyopathy, Hypertrophic

Back to Details
This is a "connection" page, showing publications William Spencer has written about Cardiomyopathy, Hypertrophic.
William Spencer
Connection Strength
4.150
Cardiomyopathy, Hypertrophic
  1. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011 Nov 22; 58(22):2322-8.
    View in: PubMed
    Score: 0.363
  2. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv. 2008 Oct; 1(5):561-70.
    View in: PubMed
    Score: 0.292
  3. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy--the Baylor experience (1996-2002). Clin Cardiol. 2005 Mar; 28(3):124-30.
    View in: PubMed
    Score: 0.228
  4. Images in cardiovascular medicine. Avoiding papillary muscle infarction with myocardial contrast echocardiographic guidance of nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2004 Feb 10; 109(5):e27-8.
    View in: PubMed
    Score: 0.212
  5. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: short-term results in 50 consecutive procedures. Clin Cardiol. 2003 Jun; 26(6):275-9.
    View in: PubMed
    Score: 0.202
  6. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am Heart Hosp J. 2003; 1(1):83-90.
    View in: PubMed
    Score: 0.196
  7. Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot study. J Med Syst. 2002 Aug; 26(4):293-300.
    View in: PubMed
    Score: 0.190
  8. Role of controlled septal infarct in hypertrophic obstructive cardiomyopathy. Cardiol Rev. 2002 Mar-Apr; 10(2):108-18.
    View in: PubMed
    Score: 0.185
  9. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001 Nov 15; 38(6):1701-6.
    View in: PubMed
    Score: 0.181
  10. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001 Mar 20; 103(11):1492-6.
    View in: PubMed
    Score: 0.173
  11. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol. 2000 Sep; 36(3):852-5.
    View in: PubMed
    Score: 0.167
  12. Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry. Circulation. 2000 Aug 08; 102(6):600-1.
    View in: PubMed
    Score: 0.166
  13. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999 Oct; 34(4):1123-8.
    View in: PubMed
    Score: 0.156
  14. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 1999 Jan 26; 99(3):344-7.
    View in: PubMed
    Score: 0.149
  15. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1998 Jul; 32(1):225-9.
    View in: PubMed
    Score: 0.143
  16. Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol. 1997 May; 20(5):417-8.
    View in: PubMed
    Score: 0.132
  17. Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
    View in: PubMed
    Score: 0.085
  18. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
    View in: PubMed
    Score: 0.074
  19. Initial experience with alcohol septal ablation using a novel magnetic navigation system. J Interv Cardiol. 2007 Dec; 20(6):559-63.
    View in: PubMed
    Score: 0.069
  20. Depression, anxiety, and quality of life in patients with obstructive hypertrophic cardiomyopathy three months after alcohol septal ablation. Am J Cardiol. 2007 Nov 15; 100(10):1592-7.
    View in: PubMed
    Score: 0.069
  21. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007 Aug 21; 50(8):795-8.
    View in: PubMed
    Score: 0.067
  22. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005 Dec; 28(12):1354-6.
    View in: PubMed
    Score: 0.060
  23. Effectiveness of percutaneous intervention for patients with obstructive hypertrophic cardiomyopathy and coronary artery disease. Am J Cardiol. 2005 Aug 15; 96(4):580-1.
    View in: PubMed
    Score: 0.059
  24. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.057
  25. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004 Feb 24; 109(7):824-7.
    View in: PubMed
    Score: 0.053
  26. Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy. Am Heart J. 2003 Dec; 146(6):1112-4.
    View in: PubMed
    Score: 0.052
  27. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003 Nov 05; 42(9):1687-713.
    View in: PubMed
    Score: 0.052
  28. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003 Jul 16; 42(2):296-300.
    View in: PubMed
    Score: 0.051
  29. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002 Dec 18; 40(12):2165-73.
    View in: PubMed
    Score: 0.049
  30. Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation. J Nucl Cardiol. 2002 Nov-Dec; 9(6):594-600.
    View in: PubMed
    Score: 0.048
  31. Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2002 Jul 23; 106(4):412-5.
    View in: PubMed
    Score: 0.047
  32. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation. 2001 Apr 10; 103(14):1844-50.
    View in: PubMed
    Score: 0.043
  33. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001 Jan; 37(1):208-14.
    View in: PubMed
    Score: 0.043
  34. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation. 1999 Jan 19; 99(2):254-61.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.